Inventiva S.A. American Depository Shares (IVA) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with IVA
Recent news

Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
IVA

Inventiva Q2 Earnings Call Highlights
Inventiva Q2 Earnings Call Highlights
IVA

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
IVA

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
IVA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.70
- MACD 12/26/9
- -0.25
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.01
- SMA 50
- $4.23
- Price below SMA 50
- EMA 50
- $4.02
- Price below EMA 50
- SMA 200
- $5.00
- Price below SMA 200
- EMA 200
- $4.71
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
IVA

Inventiva Q2 Earnings Call Highlights
Inventiva Q2 Earnings Call Highlights
IVA

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
IVA

Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
IVA

Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?
Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect?
IVA

Biotech Inventiva's 50% surge shows investor optimism over liver disease drug
Biotech Inventiva's 50% surge shows investor optimism over liver disease drug
IVA

Are You Looking for a Top Momentum Pick? Why Inventiva S.A.
Are You Looking for a Top Momentum Pick? Why Inventiva S.A.
IVA

Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know
Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know
IVA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew Obenshain | Chief Executive Officer | 1974 |
| Dr. Pierre Broqua Ph.D. | Co-Founder | 1962 |
| Mr. Jean Volatier | Executive VP Finance & Corporate Social Responsibility | 1965 |
| Dr. Martine Zimmermann Pharm.D. | Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs | 1969 |
| Mr. Jason A. Campagna M.D., Ph.D. | President of Research & Development and Chief Medical Officer | 1966 |
| Mr. Axel-Sven Malkomes | Chief Financial Officer | 1967 |
| Ms. Susan Coles | Chief Legal Officer | 1966 |
| Ms. Pamela Herbster | Chief People Officer | — |
| Ms. Nazira Amra M.D. | Chief Commercial Strategy Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 35.70
- MACD 12/26/9
- -0.25
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.01
- SMA 50
- $4.23
- Price below SMA 50
- EMA 50
- $4.02
- Price below EMA 50
- SMA 200
- $5.00
- Price below SMA 200
- EMA 200
- $4.71
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $17.67
- High
- $21.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.5 | +9.8 | -11.8 | -5.5 | -0.8 | -20.8 | +21.4 | +10.1 | -22.6 | -4.0 |



